Form 4: Director Jake Simson Receives Stock Options at Bicara
Statement of Changes in Beneficial Ownership
Director Jake Simson was granted 19,475 stock options in Bicara Therapeutics Inc. as part of his service arrangement.
Summary
- Director Jake Simson received a grant of 19,475 stock options on June 9, 2026.
- The options have an exercise price of $20.56 per share.
- The options vest on the earlier of June 9, 2027, or the date of the next Annual Meeting of Stockholders.
- The reporting person holds these options for the benefit of RA Capital Management, L.P. and disclaims beneficial ownership.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified in this filing.
Risks
- Vesting is subject to the reporting person's continued service on the vesting date.
Future Outlook
The options are set to vest in one year, contingent upon continued service.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to oversee long-term company performance.
Comparison to Industry Standards
- The grant of stock options to non-employee directors is consistent with standard compensation practices for NASDAQ-listed biotechnology companies.
- The one-year vesting schedule is typical for annual director equity awards.
Related Party Transactions
- The reporting person holds the options for the benefit of RA Capital Management, L.P. and is obligated to turn over net proceeds to the Adviser to offset advisory fees.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard director compensation event.
Next Steps
- Vesting of options on June 9, 2027, or the next Annual Meeting of Stockholders.
Key Dates
| Date | Description |
|---|---|
| 06/09/2026 | Transaction date of the stock option grant. |
| 06/09/2027 | Vesting date for the stock options. |
| 06/09/2036 | Expiration date of the stock options. |
Keywords
Bicara Therapeutics, BCAX, Form 4, Stock Options, Insider Trading, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.